128 related articles for article (PubMed ID: 14967453)
21. The EGF receptor family as targets for cancer therapy.
Mendelsohn J; Baselga J
Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
23. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
24. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
25. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
26. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A
Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423
[TBL] [Abstract][Full Text] [Related]
27. An overview of HER-targeted therapy with lapatinib in breast cancer.
McArthur H
Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
[TBL] [Abstract][Full Text] [Related]
28. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
29. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
30. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
31. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Kim R; Toge T
Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of HER-2 inhibitors.
Rabindran SK
Cancer Lett; 2005 Sep; 227(1):9-23. PubMed ID: 16051028
[TBL] [Abstract][Full Text] [Related]
33. Targeting HER1/EGFR: a molecular approach to cancer therapy.
Arteaga C
Semin Oncol; 2003 Jun; 30(3 Suppl 7):3-14. PubMed ID: 12840796
[TBL] [Abstract][Full Text] [Related]
34. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer.
Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4436s-4440s. PubMed ID: 16857824
[TBL] [Abstract][Full Text] [Related]
35. HER-targeted tyrosine-kinase inhibitors.
Baselga J; Hammond LA
Oncology; 2002; 63 Suppl 1():6-16. PubMed ID: 12422050
[TBL] [Abstract][Full Text] [Related]
36. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Normanno N; Bianco C; De Luca A; Maiello MR; Salomon DS
Endocr Relat Cancer; 2003 Mar; 10(1):1-21. PubMed ID: 12653668
[TBL] [Abstract][Full Text] [Related]
37. HER1/EGFR targeting: refining the strategy.
Pérez-Soler R
Oncologist; 2004; 9(1):58-67. PubMed ID: 14755015
[TBL] [Abstract][Full Text] [Related]
38. Rational therapeutic intervention in cancer: kinases as drug targets.
Sawyers CL
Curr Opin Genet Dev; 2002 Feb; 12(1):111-5. PubMed ID: 11790564
[TBL] [Abstract][Full Text] [Related]
39. The ErbB receptor family: a therapeutic target for cancer.
de Bono JS; Rowinsky EK
Trends Mol Med; 2002; 8(4 Suppl):S19-26. PubMed ID: 11927283
[TBL] [Abstract][Full Text] [Related]
40. HER family inhibitors in pancreatic cancer: current status and future directions.
Berz D; Miner T; McCormack E; Safran H
Expert Opin Ther Targets; 2007 Mar; 11(3):337-47. PubMed ID: 17298292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]